#Switzerland #NLS Pharmaceutics #Zurich #Kadimastem #NewcelX Ltd.

NLS Pharmaceutics to Undergo Major Changes Ahead of Merger

In a significant development for investors and stakeholders, NLS Pharmaceutics Ltd. (NASDAQ: NLSP) has announced plans to execute a reverse share split and change its name in anticipation of its upcoming merger with Kadimastem Ltd. This strategic move aims to enhance the company's market position and operational efficiency.

What Does the Reverse Share Split Entail?

Starting October 31, 2025, NLS Pharmaceutics will implement a 1-for-10 reverse share split. This means that for every ten shares currently held, shareholders will receive one new share. The existing shares will be adjusted for their par value from CHF 0.03 to CHF 0.05 post-split. Such a move is generally utilized to bolster the stock price and make shares more attractive to investors on the market.

An important aspect of this change is the announcement of a new trading ticker symbol, NCEL, which will replace the previous symbols after the share split becomes effective. This reflects not just a mere administrative change, but a fundamental shift in NLS's identity as it transitions to NewcelX Ltd. following the merger.

The Merger with Kadimastem

The merger with Kadimastem, a company renowned for its innovations in cell therapies targeting neurodegenerative diseases and diabetes, presents an exciting opportunity for NLS Pharmaceutics. Following the merger, NLS is poised to enhance its research initiatives and tap into Kadimastem's advanced therapeutic capabilities. This merger has the potential to create a stronger entity better equipped to navigate the biopharmaceutical landscape.

The new combined entity will seek to accelerate the development of therapies tailored for patients suffering from rare and complex central nervous system disorders, a mission aligned with both companies' goals in biopharmaceutical innovation.

Implications for Shareholders

After the execution of the reverse split and closing of the merger, the total outstanding shares for NLS Pharmaceutics will be significantly reduced. The expected total will be 4,558,378 common shares post-merger adjustment. Importantly, all existing options and warrants will also undergo appropriate adjustments to align with the new structure.

Investors will not see any fractional shares issued due to the reverse split; instead, any fractions will convert into cash payments. This ensures that all shareholders maintain their proportional ownership stakes, notwithstanding minor effects on voting power from the treatment of such fractional shares.

Looking Ahead

The merger and the reverse share split, both approved during the extraordinary shareholders' meeting held on September 29, 2025, are pivotal for NLS Pharmaceutics as they aim to create a more agile and competitive organization in the biopharmaceutical field. The changes, effective from October 30, 2025, are seen as steps toward fostering an innovative environment capable of delivering next-generation therapies for patients in need.

As NLS Pharmaceutics embarks on this transformative journey, stakeholders can anticipate enhanced operational effectiveness and an enhanced research pipeline that can lead to breakthroughs in patient care and therapy development.

For ongoing information and updates regarding these corporate changes, investors and interested parties are encouraged to monitor announcements from the company. More details can also be found on NLS Pharmaceutics’ official website, www.nlspharma.com.